GSK: 3 Key Takeaways for Long-Term Investors

Source Motley_fool

Key Points

  • GSK started 18 phase 3 clinical trials in 2026.

  • Specialty medicine sales grew 15% in the third quarter.

  • Year-to-date cash generation reached GBP 7.4 billion.

  • Motley Fool Issues Rare "Total Conviction" Buy Alert ›

On its third-quarter 2026 earnings call, held on Oct. 28, 2026, GSK (NYSE:GSK) reconfirmed its full-year 2026 guidance as sales grew 5% to GBP 8.9 billion. This commercial trajectory shows how effectively the drugmaker transitions from legacy primary-care treatments toward high-margin specialty therapies. Three things management said stand out.

1. Pipeline Acceleration Expands Late-Stage Clinical Trials

The drugmaker is accelerating its research and development (R&D) pipeline to generate long-term organic growth. It has initiated 18 phase 3 clinical trials in 2026 and expects to reach 22 by the end of the year.

Across R&D, we continue to make fantastic progress in accelerating our late-stage pipeline. ... We've now started 18 phase III studies, with a further four on track to start before the end of the year.
-- Tony Wood, Pipeline Update

2. Specialty Medicines Drive Revenue Growth and Market Share

Specialty medicines, including long-acting human immunodeficiency virus (HIV) treatments, grew 15% in the third quarter. These higher-margin therapies offset broader price pressures across the inhaler market.

Commercial momentum continued in the Q3, driven mainly by specialty medicines, up 15%. ... Cabenuva remains the only long-acting injectable regimen for HIV treatment, establishing a strong foundation with patients who prefer to take medicines less frequently.
-- Nina Mojas, Growth Drivers

3. Restructuring Program Reallocates Capital to Core Assets

Management launched the Accelerate Growth program to streamline support operations and supply chain logistics. The program redirects savings toward late-stage drug development while maintaining operating profit margins.

Operating profit grew 5%, with the margin broadly stable, as increased R&D investment was broadly offset by cost of goods and SG&A productivity as we further match our cost base to the evolving portfolio.
-- Julie Brown, Financial Performance

Looking Ahead

Operating momentum in specialty launches positions the business well for full-year performance. Structural advantages in long-acting HIV regimens and expanded oncology indications provide lasting pricing power, while management tracks pricing discipline across respiratory lines.

Looking ahead, we remain on track to deliver our full year 2026 guidance. Sales are expected in the upper half of the range, driven by specialty performance.
-- Julie Brown, Financial Performance

Long-term value creation relies on executing this accelerated development program while maintaining strict cost control.

To close, we remain focused on executing our strategy, which is built on driving top-line growth, building and accelerating the late-stage portfolio, and actively reallocating resources to where they can create the largest value for patients and shareholders.
-- Luke Miels, Chief Executive Officer

Should you buy stock in GSK right now?

Before you buy stock in GSK, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and GSK wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $335,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,000,640!*

Now, it’s worth noting Stock Advisor’s total average return is 823% — a market-crushing outperformance compared to 208% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of November 17, 2026.

The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Bitcoin Price Outlook For November 2026: One Price Level Remains CriticalBitcoin price enters November defending $76,000, the average cost basis of short-term holders. The level was held after the Binance hack pushed BTC to a six-week low of $76,275.The shock from Binance
Author  Beincrypto
Nov 03, Tue
Bitcoin price enters November defending $76,000, the average cost basis of short-term holders. The level was held after the Binance hack pushed BTC to a six-week low of $76,275.The shock from Binance
placeholder
AMD Just Had Its Biggest Run Against Nvidia Since 1999. Can It Survive Earnings?AMD outperformed Nvidia by 53.2 percentage points over five trading days, according to The Kobeissi Letter. That is the widest gap between the two chipmakers since Nvidia went public in January 1999.T
Author  Beincrypto
Yesterday 02: 27
AMD outperformed Nvidia by 53.2 percentage points over five trading days, according to The Kobeissi Letter. That is the widest gap between the two chipmakers since Nvidia went public in January 1999.T
placeholder
Market News Today Australia: VIX Jumps Nearly 19%, Gold Hits One-Year Low and Nasdaq 100 FallsNasdaq 100 falls 2.67%, gold hits a one-year low and WTI settles at US$85.72. See what Australian traders are watching ahead of Nvidia earnings.
Author  Mitrade Team
3 hours ago
Nasdaq 100 falls 2.67%, gold hits a one-year low and WTI settles at US$85.72. See what Australian traders are watching ahead of Nvidia earnings.
placeholder
Stocks, Gold, and Asia Bleed $2.2 Trillion: Top 5 Factors That Triggered the CrashGlobal markets lost roughly $2.2 trillion on November 16 as US stocks, precious metals, and Asian equities sold off together. Technology and AI-linked names led the decline.However, the rout did not s
Author  Beincrypto
2 hours ago
Global markets lost roughly $2.2 trillion on November 16 as US stocks, precious metals, and Asian equities sold off together. Technology and AI-linked names led the decline.However, the rout did not s
placeholder
Nvidia faces its biggest earnings test yet — why Silicon Valley billionaires want Jensen Huang backNvidia faces a critical earnings test as investors weigh its AI growth outlook and leadership uncertainty. Discover why Silicon Valley billionaires want Jensen Huang back, what it could mean for Nvidia shares and how the results may shape the broader AI trade.
Author  Mark Garro
2 hours ago
Nvidia faces a critical earnings test as investors weigh its AI growth outlook and leadership uncertainty. Discover why Silicon Valley billionaires want Jensen Huang back, what it could mean for Nvidia shares and how the results may shape the broader AI trade.
goTop
quote